The objectives of this proposal are two-fold: 1) to provide the chlamydial research community with a genetic tool kit (based upon a mobile, targetable group II intron [TargeTron, Sigma]) that will allow us to tackle questions not before feasible, and 2) to use these tools to test the essentiality of the polymorphic outer membrane proteins (Pmps), a collection of phase variable chlamydial proteins linked to virulence. To address our first goal, we will expand the utility of the TargeTron system by enabling its use in different Chlamydia species and C. trachomatis serovars through the development of non-ampicillin based selection and screening markers. In addition, we will modify this platform for use in gene editing and random mutagenesis approaches.
In Aim 2, we seek to determine the essentiality of C. trachomatis pmps using the optimal intron-platform developed in Aim 1 to target each pmp for insertional inactivation. These autotransporter proteins are conserved throughout Chlamydia spp. and have been associated with virulence in humans. Elucidating which Pmps (C. trachomatis possesses nine pmps) are required for growth will allow future research efforts to focus on those Pmps critical for pathogen survival. Collectively, our studies will provide a powerful set of molecular tools to help advance research aimed at vaccine development and treatment strategies, while also filling a knowledge gap regarding the importance of Pmp function to chlamydial pathogenesis.

Public Health Relevance

The Chlamydia are a group of bacterial pathogens responsible for a variety of infections in humans including pneumonia, trachoma, and sexually transmitted infections (of which over 1.4 million cases were reported in 2012 in the United States). Research on these important pathogens has been hindered by a paucity of molecular biology tools to manipulate the genomes of these organisms. Our proposal seeks to further develop a method for constructing chlamydial mutants that will allow the research community to pursue new avenues of exploration aimed towards treating and preventing infections.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI115238-01
Application #
8808631
Study Section
Special Emphasis Panel (ZRG1-IDM-B (80))
Program Officer
Hiltke, Thomas J
Project Start
2015-04-15
Project End
2017-03-31
Budget Start
2015-04-15
Budget End
2016-03-31
Support Year
1
Fiscal Year
2015
Total Cost
$221,250
Indirect Cost
$71,250
Name
Southern Illinois University Carbondale
Department
Microbiology/Immun/Virology
Type
Schools of Arts and Sciences
DUNS #
939007555
City
Carbondale
State
IL
Country
United States
Zip Code
62901
Shaw, Jennifer H; Key, Charlotte E; Snider, Timothy A et al. (2018) Genetic Inactivation of Chlamydia trachomatis Inclusion Membrane Protein CT228 Alters MYPT1 Recruitment, Extrusion Production, and Longevity of Infection. Front Cell Infect Microbiol 8:415
Cossé, Mathilde M; Barta, Michael L; Fisher, Derek J et al. (2018) The Loss of Expression of a Single Type 3 Effector (CT622) Strongly Reduces Chlamydia trachomatis Infectivity and Growth. Front Cell Infect Microbiol 8:145
Illingworth, Melissa; Hooppaw, Anna J; Ruan, Lu et al. (2017) Biochemical and Genetic Analysis of the Chlamydia GroEL Chaperonins. J Bacteriol 199:
Key, Charlotte E; Fisher, Derek J (2017) Use of Group II Intron Technology for Targeted Mutagenesis in Chlamydia trachomatis. Methods Mol Biol 1498:163-177
Hooppaw, Anna J; Fisher, Derek J (2015) A Coming of Age Story: Chlamydia in the Post-Genetic Era. Infect Immun 84:612-21
Thompson, Christopher C; Griffiths, Cherry; Nicod, Sophie S et al. (2015) The Rsb Phosphoregulatory Network Controls Availability of the Primary Sigma Factor in Chlamydia trachomatis and Influences the Kinetics of Growth and Development. PLoS Pathog 11:e1005125
Lowden, Nicole M; Yeruva, Laxmi; Johnson, Cayla M et al. (2015) Use of aminoglycoside 3' adenyltransferase as a selection marker for Chlamydia trachomatis intron-mutagenesis and in vivo intron stability. BMC Res Notes 8:570